Ameritas Investment Partners’s Forte Biosciences FBRX Stock Holding History

Ameritas Investment Partners’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-35	Closed	-$1K	–	3122
2022 Q1	$1K	Hold	35	–	–	﹤0.01%	3062
2021 Q4	$2K	Hold	35	–	–	﹤0.01%	3092
2021 Q3	$3K	Hold	35	–	–	﹤0.01%	3062
2021 Q2	$30K	Buy	+35	New	+$31.5K	﹤0.01%	2498
2020 Q2	–	Sell	-4	Closed	-$2K	–	3086
2020 Q1	$2K	Hold	4	–	–	﹤0.01%	2962
2019 Q4	$1K	Hold	4	–	–	﹤0.01%	2996
2019 Q3	$1K	Hold	4	–	–	﹤0.01%	3044
2019 Q2	$10K	Hold	4	–	–	﹤0.01%	2800
2019 Q1	$17K	Hold	4	–	–	﹤0.01%	2456
2018 Q4	$13K	Hold	4	–	–	﹤0.01%	2552
2018 Q3	$24K	Hold	4	–	–	﹤0.01%	2413
2018 Q2	$14K	Hold	4	–	–	﹤0.01%	2692
2018 Q1	$18K	Hold	4	–	–	﹤0.01%	2470
2017 Q4	$16K	Buy	4 +2	+100%	+$7.98K	﹤0.01%	2543
2017 Q3	$10K	Hold	2	–	–	﹤0.01%	2766
2017 Q2	$9K	Buy	+2	New	+$11.3K	﹤0.01%	2840

Other funds holding FBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ameritas Investment Partners's FBRX Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Forte Biosciences (FBRX) in Q2 2022, closing a stake of 35 shares — an estimated $1K sold.

Ameritas Investment Partners first reported a position in FBRX in Q2 2017 and held it in 16 quarters. The position peaked at $30K in Q2 2021. 39 funds tracked by Wall St. Rank hold FBRX as of Q2 2022.

Ameritas Investment Partners reported no remaining Forte Biosciences position as of Q2 2022 after selling out during the quarter.
Ameritas Investment Partners sold 35 Forte Biosciences shares in Q2 2022, an estimated $1K.
Ameritas Investment Partners first reported a position in Forte Biosciences in Q2 2017 and held it in 16 quarters.
Ameritas Investment Partners's Forte Biosciences position peaked at $30K in Q2 2021.
39 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.